ARDS
Price:
$0.001
Market Cap:
$44.57K
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials t...[Read more]
Industry
Biotechnology
IPO Date
2018-08-14
Stock Exchange
NASDAQ
Ticker
ARDS
According to Aridis Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -21.32%. This represents a change of 161.22% compared to the average of -8.16% of the last 4 quarters.
The mean historical ROE of Aridis Pharmaceuticals, Inc. over the last ten years is -68.41%. The current -21.32% ROE has changed -68.84% with respect to the historical average. Over the past ten years (40 quarters), ARDS's ROE was at its highest in in the September 2021 quarter at 505.46%. The ROE was at its lowest in in the March 2018 quarter at -193.61%.
Average
-68.41%
Median
-61.14%
Minimum
-797.19%
Maximum
299.65%
Discovering the peaks and valleys of Aridis Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 848.99%
Maximum Annual ROE = 299.65%
Minimum Annual Increase = -131.67%
Minimum Annual ROE = -797.19%
Year | ROE | Change |
---|---|---|
2022 | 126.89% | -57.65% |
2021 | 299.65% | 18.68% |
2020 | 252.49% | -131.67% |
2019 | -797.19% | 848.99% |
2018 | -84.00% | -61.04% |
2017 | -215.60% | 252.63% |
The current ROE of Aridis Pharmaceuticals, Inc. (ARDS) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
226.35%
5-year avg
-40.43%
10-year avg
-68.41%
Aridis Pharmaceuticals, Inc.’s ROE is less than Akari Therapeutics, Plc (1.04%), greater than Aditxt, Inc. (-607.01%), greater than ABVC BioPharma, Inc. (-132.83%), greater than Acasti Pharma Inc. (-18.84%), greater than Sigilon Therapeutics, Inc. (-81.98%), less than Reviva Pharmaceuticals Holdings, Inc. (7.96%), greater than ZyVersa Therapeutics, Inc. (-172.51%), less than Kiromic BioPharma, Inc. (337.72%), less than Unicycive Therapeutics, Inc. (294.74%), greater than Avenue Therapeutics, Inc. (-749.10%), greater than Hoth Therapeutics, Inc. (-81.79%), greater than Revelation Biosciences, Inc. (-243.91%), greater than NeuroBo Pharmaceuticals, Inc. (-154.04%), greater than Virax Biolabs Group Limited (-115.10%), less than Reviva Pharmaceuticals Holdings, Inc. (7.96%), greater than Eyenovia, Inc. (-615.55%), greater than Cognition Therapeutics, Inc. (-118.11%), greater than TransCode Therapeutics, Inc. (-597.47%), greater than Kodiak Sciences Inc. (-77.23%), greater than Dermata Therapeutics, Inc. (-197.44%),
Company | ROE | Market cap |
---|---|---|
1.04% | $38.13M | |
-607.01% | $1.61M | |
-132.83% | $8.20M | |
-18.84% | $27.58M | |
-81.98% | $56.22M | |
7.96% | $45.67M | |
-172.51% | $2.61M | |
337.72% | $2.61M | |
294.74% | $37.04M | |
-749.10% | $3.86M | |
-81.79% | $6.97M | |
-243.91% | $1.42M | |
-154.04% | $28.86M | |
-115.10% | $11.68M | |
7.96% | $34.98M | |
-615.55% | $38.45M | |
-118.11% | $24.04M | |
-597.47% | $6.04M | |
-77.23% | $139.96M | |
-197.44% | $2.96M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aridis Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aridis Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Aridis Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Aridis Pharmaceuticals, Inc. (ARDS)?
What is the highest ROE for Aridis Pharmaceuticals, Inc. (ARDS)?
What is the 3-year average ROE for Aridis Pharmaceuticals, Inc. (ARDS)?
What is the 5-year average ROE for Aridis Pharmaceuticals, Inc. (ARDS)?
How does the current ROE for Aridis Pharmaceuticals, Inc. (ARDS) compare to its historical average?